Dr. Nath Limpruttidham, MD, MPH

Dr. Limpruttidham practices at The Queen's Medical Center in Honolulu, Hawaii, part of The Queen's Health Systems.

Dr. Limpruttidham's NPI, 1619401502, was assigned on April 18, 2017. Dr. Limpruttidham holds Hawaii license MD-21033.

Dr. Limpruttidham's primary practice is The Queen's Medical Center, at 1301 Punchbowl St, Honolulu, HI 96813 in Honolulu County. The practice phone is (808) 538-9011.

Dr. Limpruttidham's primary practice is The Queen's Medical Center in Honolulu, Hawaii, part of The Queen's Health Systems. Dr. Limpruttidham is also affiliated with Queen's North Hawaiʻi Community Hospital. The medical group on file is The Queen's Medical Center. Dmand AI also links Dr. Limpruttidham to 1 more hospital, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Limpruttidham practices, 5 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Limpruttidham's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Limpruttidham is licensed in Hawaii.

CMS data shows 1,503 Medicare services from Dr. Limpruttidham across 21 procedure codes in 2024, for 1,076 Medicare patients. Medicare paid $83,899 for them.

CMS counts 1,076 Medicare patients who saw Dr. Limpruttidham in 2024. The largest group is 75 to 84, with 427 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Limpruttidham's median patient age at 74, with 43% women.

In 2024, Dr. Limpruttidham wrote 629 Medicare Part D claims for 108 patients. 72% of them were for generic drugs. CMS names the drug for 490 of them, across 12 drugs with 11 or more claims each, at $253,543 in total drug cost. In 2023, CMS named 56 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Limpruttidham for performance year 2024, reported through an alternative payment model (APM). Dr. Limpruttidham accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Limpruttidham as offering telehealth.

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 21 papers to Dr. Limpruttidham, published from 2018 to 2024. 2019 was the busiest year, with 7. The most frequent topics are Cause of Death, Atrial Fibrillation and Electrocardiography. Dr. Limpruttidham has published most often in Ann Noninvasive Electrocardiol. Dr. Limpruttidham's most frequent co-authors are Pattara Rattanawong, MD, Kittika Poonsombudlert, MD and Pakawat Chongsathidkiet, MD, PhD.

CMS Open Payments shows 48 general payments to Dr. Limpruttidham from 12 drug and device companies from 2023 to 2025. Travel and lodging make up the largest share, 60% of the total. Abbott Laboratories paid the most, $3,123.